We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Genetic Association Mapping of Malaria Resistance in Anopheles Gambiae

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00850655
Recruitment Status : Completed
First Posted : February 25, 2009
Last Update Posted : October 26, 2016
Sponsor:
Information provided by (Responsible Party):

Study Description
Brief Summary:
This is a study of the genetics of malaria transmission by the mosquito vector in Africa, Anopheles gambiae. The study focuses on the mosquito vector, not the human subjects infected with malaria. DNA extracted from infected mosquitoes will be analyzed genetically by microsatellite and single-nucleotide polymorphisms (SNPs) to identify mosquito genes that control mosquito resistance to malaria parasites.

Condition or disease
Malaria

Detailed Description:
A standard diagnostic blood smear from a drop of blood will be carried out on 20 study subjects once per month. One malaria-positive subject from among the 20 will be asked to donate 5cc of blood, also no more frequently than once per month. The blood will be placed in a water-jacketed heated membrane feeding device that will be positioned on top of a cage of mosquitoes. The mosquitoes are attracted to the warmth and drink the blood through the artificial skin-like membrane. The goal of the research is to study the infected mosquitoes. No studies will be carried out on the human subjects. The point of human subjects involvement is to obtain the naturally malaria-infected blood for feeding of mosquitoes. After blood feeding, the mosquitoes are held in an environmental chamber for one week, at which time they are dissected to count numbers of malaria parasites developing on the mosquito stomach wall. This number constitutes the quantitative phenotype, and we extract genomic DNA from the carcass for genetic marker typing, which constitutes the genotype. Genetic linkage analysis identifies markers near genes that control parasite number, thus resistance or susceptibility to parasite infection.

Study Design

Study Type : Observational
Actual Enrollment : 20 participants
Observational Model: Ecologic or Community
Time Perspective: Cross-Sectional
Official Title: Genetic Association Mapping of Malaria Resistance in Anopheles Gambiae
Study Start Date : March 2008
Primary Completion Date : March 2015
Study Completion Date : March 2015

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Malaria
U.S. FDA Resources

Groups and Cohorts


Outcome Measures

Primary Outcome Measures :
  1. mosquito infection [ Time Frame: one week ]
    Protocol involves non-invasive blood draw from participant screened by finger-prick for infection with malaria. Drawn blood (0.5cc) is placed in artificial membrane feeder for feeding of mosquitoes. Primary outcome is infection of mosquitoes, detectable one week after blood feeding.


Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   5 Years to 10 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
community sample
Criteria

Inclusion Criteria:

  • 5-10 years old, and general good health

Exclusion Criteria:

  • Outside age group
  • Specific diagnosable health problems
  • General poor health
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00850655


Locations
United States, Minnesota
University of Minnesota
Saint Paul, Minnesota, United States, 55108
Sponsors and Collaborators
University of Minnesota - Clinical and Translational Science Institute
Investigators
Principal Investigator: Kenneth D Vernick, PhD University of Minnesota - Clinical and Translational Science Institute
More Information

Responsible Party: University of Minnesota - Clinical and Translational Science Institute
ClinicalTrials.gov Identifier: NCT00850655     History of Changes
Other Study ID Numbers: 0607M88827
First Posted: February 25, 2009    Key Record Dates
Last Update Posted: October 26, 2016
Last Verified: October 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Additional relevant MeSH terms:
Malaria
Protozoan Infections
Parasitic Diseases